B+
Bull case
20%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
ALDX
Aldeyra TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.60
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-06
Recent news sentiment (30D)
-0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+96.0
Score
AI commentary
The available headline narrative is mixed-to-negative, dominated by the FDA rejection and regulatory uncertainty, while positive pipeline and runway context is older. A June CEO open-market purchase is secondary alignment evidence only and does not establish operating improvement [#SEC-FORM4-2026-06-05]. Social, options, short-interest, employee-review, and analyst-revision data are unavailable; zeros indicate unavailable data, not neutral evidence. This remains a low-coverage, event-driven monitoring view.
RankAlpha Sentiment Codex - 2026-09-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-05eventFDA interaction and potential resubmission planHigh impact
The company reported that it scheduled a Type A meeting with the FDA to understand actions needed for reproxalap approval. A clearer regulatory plan could improve sentiment, but meeting timing and any resubmission requirements remain uncertain [#SEC-10Q-2026-05-07; #IR-2026-03-17].
2026-12-05catalystFDA complete response letter remains the dominant overhangHigh impact
Aldeyra received a March 2026 FDA complete response letter for reproxalap’s dry-eye NDA. The approval path, required actions, timing, and probability of eventual approval remain uncertain, keeping downside and event volatility elevated [#IR-2026-03-17].
2026-12-31catalystNext-generation RASP pipeline and runwayHigh impact
Aldeyra reported positive exploratory ADX-629 Phase 2 results, shifted development focus to ADX-248 and ADX-246, targeted 2026 IND filings, and extended projected operating runway into the second half of 2027. These remain early-stage optionality rather than near-term revenue drivers [#PR-EARNINGS-2025-10-28].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-06 • Updated nightlySource: Internal modelMethodology